RESEARCHER PROFILE
Laura J. Esserman
← Back to University of California, San Francisco
L
University of California, San Francisco
Laura J. Esserman works in Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, MRI in cancer diagnosis, BRCA gene mutations in cancer, Digital Radiography and Breast Imaging. Recorded institutional associations include University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center.
988Publications
36,531Citations
94H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
2006 · 1,317 citationsWhole-genome analysis informs breast cancer response to aromatase inhibition
2012 · 1,023 citationsRisk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial
2013 · 831 citationsTargeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
2010 · 772 citationsI-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
2009 · 766 citationsEffect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
2020 · 707 citationsBreast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
2012 · 625 citationsThe Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
2020 · 564 citationsAdaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
2016 · 554 citationsRandomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
2011 · 551 citationsRethinking Screening for Breast Cancer and Prostate Cancer
2009 · 516 citationsLocally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
2012 · 502 citationsAddressing overdiagnosis and overtreatment in cancer: a prescription for change
2014 · 501 citationsLeukocyte composition of human breast cancer
2011 · 479 citationsOverdiagnosis and Overtreatment in Cancer
2013 · 467 citationsCirculating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
2020 · 462 citationsResidual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
2021 · 456 citationsAdaptive Randomization of Neratinib in Early Breast Cancer
2016 · 454 citationsPathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
2012 · 438 citationsPersonalized early detection and prevention of breast cancer: ENVISION consensus statement
2020 · 438 citationsAdaptive platform trials: definition, design, conduct and reporting considerations
2019 · 412 citationsUtility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging
1999 · 379 citationsMYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
2012 · 378 citationsKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
2017 · 366 citationsChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
2011 · 362 citations
